author-photo

Alex C. Spyropoulos

Hofstra University
Lenox Hill Hospital
The Feinstein Institute for Medical Research

195

Papers

9105

Citations

Citation Trend

Filter By

Papers (195) Sort By

Journal Conference Others

Rivaroxaban for extended thromboprophylaxis in acutely ill medical patients 75 years of age or older.

2021 Journal of Thrombosis and Haemostasis
Show All
- Source
- Cite
- Save
Citations (0)
Current practices of standardized risk assessment for venous thromboembolism: results from a global survey from the World Thrombosis Day steering committee.

2021 Journal of Thrombosis and Haemostasis
Show All
- Source
- Cite
- Save
Citations (0)
Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial.

2021 JAMA Internal Medicine
Show All
- Source
- Cite
- Save
Citations (8)
Prevalence and Predictors of Venous Thromboembolism or Mortality in Hospitalized COVID-19 Patients.

2021 Thrombosis and Haemostasis
Show All
- Source
- Cite
- Save
Citations (12)
Risk of Severe Bleeding With Extended Rivaroxaban to Prevent Venous Thromboembolism in Acute Medically Ill Patients With Bronchiectasis.

2021 Clinical and Applied Thrombosis-Hemostasis
Show All
- Source
- Cite
- Save
Citations (0)
Treatment-dose LMWH versus prophylactic/intermediate dose heparins in high risk COVID-19 inpatients: Rationale and design of the HEP-COVID Trial.

2021 Thrombosis and Haemostasis
Show All
- Source
- Cite
- Save
Citations (2)
Global reporting of pulmonary embolism–related deaths in the World Health Organization mortality database: Vital registration data from 123 countries

2021
Show All
- Source
- Cite
- Save
Citations (1)
Validation of the IMPROVE-DD risk assessment model for venous thromboembolism among hospitalized patients with COVID-19

2021
Show All
- Source
- Cite
- Save
Citations (7)
Ethnic differences in thromboprophylaxis for COVID-19 patients: should they be considered?

2021 International Journal of Hematology
Show All
- Source
- Cite
- Save
Citations (5)
Rationale and design for the study of rivaroxaban to reduce thrombotic events, hospitalization and death in outpatients with COVID-19: The PREVENT-HD study.

2021 American Heart Journal
Show All
- Source
- Cite
- Save
Citations (7)